Host-directed therapies for tackling multi-drug resistant tuberculosis: Learning from the pasteur-bechamp debates

Clinical Infectious Diseases

Volumn 61, Issue 9, 2015, Pages 1432-1438

  Zumla, Alimuddin ^a,c   Maeurer, Markus ^b,c   Chakaya, Jeremiah ^c   Hoelscher, Michael ^c   Ntoumi, Francine ^c   Rustomjee, Roxana ^c   Vilaplana, Cristina ^c   Yeboah Manu, Dorothy ^c   Rasolofo, Voahangy ^c   Munderi, Paula ^c   Singh, Nalini ^c   Aklillu, Eleni ^c   Padayatchi, Nesri ^c   Macete, Eusebio ^c   Kapata, Nathan ^c   Mulenga, Modest ^c   Kibiki, Gibson ^c   Mfinanga, Sayoki ^c   Nyirenda, Thomas ^c   Mboko, Leonard ^c   Garcia Basteiro, Alberto L ^c   Rakotosamimanana, Niaina ^c   Bates, Matthew ^c   Mwaba, Peter ^c   Reither, Klaus ^c   Gagneux, Sebastien ^c   Edwards, Sarah ^c   Mfinanga, Elirehema ^c   Abdulla, Salim ^c   Cardona, Pere Joan ^c   Russell, James B W ^c   Gant, Vanya ^c   Noursadeghi, Mahdad ^c   Elkington, Paul ^c   Bonnet, Maryline ^c   Menendez, Clara ^c   Dieye, Tandakha N ^c   Diarra, Bassirou ^c   Maiga, Almoustapha ^c   Aseffa, Abraham ^c   Parida, Shreemanta ^c   Wejse, Christian ^c   Petersen, Eskild ^c   Kaleebu, Pontiano ^c   Oliver, Matt ^c   Craig, Gill ^c   Corrah, Tumena ^c   Tientcheu, Leopold ^c   Antonio, Martin ^c   McHugh, Timothy D ^c   Sheikh, Aziz ^c   Ippolito, Giuseppe ^c   Ramjee, Gita ^c   Kaufmann, Stefan H E ^c   Churchyard, Gavin ^c   Steyn, Adrie J C ^c   Grobusch, Martin P ^c   Sanne, Ian ^c   Martinson, Neil ^c   Mandansein, Rajhmun ^c   Wilkinson, Robert J ^c   Wallis, Robert S ^c   Mayosi, Bongani ^c   Schito, Marco ^c   more..

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b KAROLINSKA INSTITUTE   (Sweden)

^c NONE

Author keywords

host directed therapy; multi drug resistant tuberculosis; repurposed drugs; treatment; tuberculosis

Indexed keywords

BCG VACCINE; TUBERCULOSTATIC AGENT;

ADAPTIVE IMMUNITY; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIAL CLEARANCE; BIOLOGICAL THERAPY; CELL THERAPY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HOST DIRECTED THERAPY; HUMAN; IMMUNOTHERAPY; INNATE IMMUNITY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TUBERCULOSIS CONTROL; DRUG EFFECTS; MULTIMODALITY CANCER THERAPY; PERSONALIZED MEDICINE; PROCEDURES; TIME FACTOR; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; COMBINED MODALITY THERAPY; HUMANS; MYCOBACTERIUM TUBERCULOSIS; PRECISION MEDICINE; TIME FACTORS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84946753369     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ631     Document Type: Review

References (46)

1. World Health Organisation. Global Tuberculosis report 2014. Available at: http://www.who.int/tb/publications/global-report/en/. Accessed 10 June 2015.
2. World Health Organization. Towards tuberculosis elimination: an action framework for low-incidence countries. report 2014. Available at: http://apps.who.int/iris/bitstream/10665/132231/1/9789241507707-eng. pdf?ua=1. Accessed 7 August 2015.
3. Migliori GB, Lienhardt C, Weyer K, van der Werf MJ, Blasi F, Raviglione MC. Ensuring rational introduction and responsible use of new TB tools. Outcome of an ERS multi-sectoral Consultation. Eur Respir J 2014; 44:1412-7.
4. Zumla A, Grange JM. Multidrug-resistant tuberculosis-can the tide be turned? Lancet Infect Dis 2001; 1:199-202.
5. Zumla A, Mwaba P, Huggett J, Kapata N, Chanda D, Grange J. Reflections on the white plague. Lancet Infect Dis 2009; 9:197-202.
6. Herbert N, George A, Masham of Ilton, et al.World TB Day 2014: finding the missing 3 million. Lancet 2014; 383:1016-8.
7. McNerney R, Maeurer M, Abubakar I, et al. Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities. J. Infect Dis 2012; 205(suppl 2):S147-58.
8. Dawson R, Diacon AH, Everitt D, et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, openlabel, partly randomised trial in patients with drug-susceptible or drugresistant pulmonary tuberculosis. Lancet 2015; 385:1738-47.
9. Zumla AI, Gillespie SH, Hoelscher M, et al. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet Infect Dis 2014; 14:327-40.
10. Kaufmann SH, Lange C, Rao M, et al. Progress in tuberculosis vaccine development and host-directed therapies-A state of the art review. Lancet Respir Med 2014; 2:301-20.
11. Ukwaja KN, Alobu I, Ifebunandu NA, Osakwe C, Igwenyi C. Trend in case detection rate for all tuberculosis cases notified in Ebonyi, Southeastern Nigeria during 1999-2009. Pan Afr Med J 2013; 16:11.
12. Bates M, Mudenda V, Shibemba A, et al. Burden of tuberculosis at post mortem in inpatients at a tertiary referral centre in sub-Saharan Africa: a prospective descriptive autopsy study. Lancet Infect Dis 2015; 15:544-51.
13. Mudenda V, Lucas S, Shibemba A, et al. Tuberculosis and tuberculosis/HIV/AIDS-Associated mortality in Africa: the urgent need to expand and invest in routine and research autopsies. J Infect Dis 2012; 205(suppl 2):S340-6.
14. Kilale AM, Kimaro GD, Kahwa AM, et al. High prevalence of tuberculosis diagnosed during autopsy examination at Muhimbili National Hospital in Dar es Salaam, Tanzania. Tanzan J Health Res 2008; 10:89-94.
15. Zumla A, Abubakar I, Raviglione M, et al. Drug-resistant tuberculosis-current dilemmas, unanswered questions, challenges, and priority needs. J Infect Dis 2012; 205(suppl 2):228-40.
16. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013; 42:156-68.
17. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-Analysis. Eur Respir J 2013; 42:169-79.
18. Gillespie SH, Crook AM, McHugh TD, et al. Four-month moxifloxacinbased regimens for drug-sensitive tuberculosis. N Engl J Med 2014; 371:1577-87.
19. Merle CS, Fielding K, Sow OB, et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med 2014; 371:1588-98.
20. Jindani A, Harrison TS, Nunn AJ, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med 2014; 371:1599-608.
21. Zumla A, Chakaya J, Centis R, et al. Tuberculosis treatment and management-An update on treatment regimens, trials, new drugs and adjunct therapies. Lancet Resp Med 2015; 3:221-35.
22. Zumla A, Chakaya J, Centis R, et al. Tuberculosis treatment and management-An update on treatment regimens, trials, new drugs, and adjunct therapies. Lancet Respir Med 2015; 3:220-34.
23. Uplekar M, Weil D, Lonnroth K, et al. WHO?s new End TB Strategy. Lancet 2015 World Health Organisation Global Tuberculosis report 2014. Available at: http://www.who.int/tb/publications/global-report/en/. Accessed 7 March 2015.
24. James DG. The Hunterian oration on Louis Pasteur?s final judgement. Host reaction, soil or terrain. Trans Med Soc Lond 1982-1984; 99-100:131-47.
25. Zumla A, Atun R, Maeurer M, et al. Viewpoint: Scientific dogmas, paradoxes and mysteries of latent Mycobacterium tuberculosis infection. Trop Med Int Health 2011; 16:79-83.
26. Grange JM, Gandy M, Farmer P, Zumla A. Historical declines in tuberculosis: nature, nurture and the biosocial model. Int J Tuberc Lung Dis 2001; 5:208-12.
27. Grange JM, Zumla A. The global emergency of tuberculosis: what is the cause? J R Soc Promot Health 2002; 122:78-81.
28. Grange J, Zumla A. Tuberculosis and the poverty-disease cycle. J R Soc Med 1999; 92:105-7.
29. Daniel TM. The history of tuberculosis. Respir Med 2006; 100:1862-70.
30. Uhlin M, Andersson J, Zumla A, Maeurer M. Adjunct immunotherapies for tuberculosis. J Infect Dis 2012; 205(suppl 2):325-34.
31. Tobin DM. Host-directed therapies for tuberculosis. Cold Spring Harb Perspect Med 2015; 1:417-32.
32. Parida SK, Madansein R, Singh N, et al. Cellular therapy in Tuberculosis. Int J Infect Dis 2015; 32:32-8.
33. Bento CF, Empadinhas N, Mendes V. Autophagy in the fight against tuberculosis. DNA Cell Biol 2015; 34:228-42.
34. Wallis RS, Hafner R. Advancing host-directed therapy for tuberculosis. Nat Rev Immunol 2015; 15:255-63.
35. Zumla A, Costello A. Ethics of healthcare research in developing countries. JRSM 2002; 95:275-6.
36. Costello A, Zumla A. Moving to research partnerships in developing countries. BMJ 2000; 321:827-9.
37. Tucker TJ, Makgoba MW. Public health. Public-private partnerships and scientific imperialism. Science 2008; 320:1016-7.
38. Shuchman M, Wondimagegn D, Pain C, Alem A. Partnering with local scientists should be mandatory. Nat Med 2014; 20:12.
39. http://www.unza-uclms.org/hdt-net. Accessed 24 April 2015.
40. http://www.internationales-buero.de/african-health-networks/default1. php. Accessed 24 April 2015.
41. Hamilton CD, Swaminathan S, Christopher DJ, et al. RePORT international: advancing TB biomarker research through global collaboration. Clin Infect Dis 2015; 61(suppl 3):S155-9.
42. Zumla A, Makanga M, Nyirenda T, et al. Genesis of EDCTP2. Lancet Infect Dis 2015; 15:11-3.
43. Zumla A, Huggett J, Dheda K, Green C, Kapata N, Mwaba P. Trials and tribulations of an African-led research and capacity development programme: the case for EDCTP investments. Trop Med Int Health 2010; 15:489-94.
44. Zumla A, Petersen E, Nyirenda T, Chakaya J. Tackling the Tuberculosis Epidemic in sub-Saharan Africa-unique opportunities arising from the second European Developing Countries Clinical Trials Partnership (EDCTP) programme 2015-2024. Int J Infect Dis 2015; 32:46-9.
45. http://www.wellcome.ac.uk/funding/biomedical-science/fundingschemes/strategic-Awards-And-initiatives/wtp057105.htm. Accessed 24 April 2015.
46. http://www.mrc.ac.uk/funding/browse/mrc-dfid-African-research-leaderscheme-2014-15/. Accessed 24 April 2015.